SEC lawyers want to wade into Bio-Rad FCPA privilege dispute

The US Securities and Exchange Commission may intervene in a dispute between life sciences company Bio-Rad Laboratories and its former general counsel because the case has implications for the regulator’s whistleblower anti-retaliation rules.

Unlock unlimited access to all Global Investigations Review content